Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a …

DVT Catenacci, NC Tebbutt, I Davidenko… - The lancet …, 2017 - thelancet.com
Background Rilotumumab is a fully human monoclonal antibody that selectively targets the
ligand of the MET receptor, hepatocyte growth factor (HGF). We aimed to assess the efficacy …
被引用次数：358 相关文章
[PDF] academia.edu

[PDF][PDF] Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer …

DVT Catenacci, NC Tebbutt, I Davidenko, AM Murad… - Lancet Oncol, 2017 - academia.edu
HHS Public Access Page 1 Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line
therapy in advanced MET-positive gastric or gastrooesophageal junction cancer (RILOMET-1) …

Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a …

DVT Catenacci, NC Tebbutt, I Davidenko, AM Murad… - 2017 - ahro.austin.org.au
Rilotumumab is a fully human monoclonal antibody that selectively targets the ligand of the
MET receptor, hepatocyte growth factor (HGF). We aimed to assess the efficacy, safety, and …

Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a …

DVT Catenacci, NC Tebbutt… - The Lancet …, 2017 - pubmed.ncbi.nlm.nih.gov
Background Rilotumumab is a fully human monoclonal antibody that selectively targets the
ligand of the MET receptor, hepatocyte growth factor (HGF). We aimed to assess the efficacy …

[引用][C] Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer …

DVT Catenacci, NC Tebbutt, I Davidenko… - The Lancet …, 2017 - cir.nii.ac.jp
Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced
MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised …

Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a …

DVT Catenacci, NC Tebbutt, I Davidenko… - The Lancet …, 2017 - infona.pl
Rilotumumab is a fully human monoclonal antibody that selectively targets the ligand of the
MET receptor, hepatocyte growth factor (HGF). We aimed to assess the efficacy, safety, and …

[引用][C] Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer …

DVT Catenacci, NC Tebbutt, I Davidenko… - The Lancet …, 2017 - elibrary.ru

Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a …

DVT Catenacci, NC Tebbutt, I Davidenko… - The Lancet …, 2017 - europepmc.org
Background Rilotumumab is a fully human monoclonal antibody that selectively targets the
ligand of the MET receptor, hepatocyte growth factor (HGF). We aimed to assess the efficacy …
[HTML] nih.gov

[HTML][HTML] Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer …

DVT Catenacci, NC Tebbutt, I Davidenko… - The Lancet …, 2017 - ncbi.nlm.nih.gov
Background Rilotumumab is a fully human monoclonal antibody that selectively targets the
ligand of the MET receptor, hepatocyte growth factor (HGF). We aimed to assess the efficacy …

Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a …

DVT Catenacci, NC Tebbutt, I Davidenko, AM Murad… - The Lancet …, 2017 - Elsevier
Background Rilotumumab is a fully human monoclonal antibody that selectively targets the
ligand of the MET receptor, hepatocyte growth factor (HGF). We aimed to assess the efficacy …